Abstract
Prophyllactic HPV vaccines are efficacious in preventing persistent infections by vaccine-HPV types and related cervical disease. The maximum effect is achieved in women who are not exposed to HPV vaccine types at the time of vaccination (HPV DNA negative women). Todays published data demonstrate equal clinical vaccine efficacy in women between 15 and 26 years and women between 24 and 45 years. The public health effect of vaccinating women older than 25 years is not clear yet, but may be smaller than after vaccination of adolescents. Unresolved issues are duration of protection and long-term preventive effects after treatment of HPV-related disease or natural clearance of HPV infection. Furthermore, it remains difficult to define subgroups of older women who would benefit from the vaccine. It may be that older women exposed to HPV or who are being treated for HPV related disease will benefit most at long term. This needs longer follow-up of vaccinated women and more detailed analysis of data from vaccine trials.
Keywords: HPV, vaccine, cervical neoplasia, adult women, prevention, review HPV vaccination in adult women
Current Cancer Therapy Reviews
Title: HPV Vaccination in Women Above 25 Years: Reasons Why?
Volume: 6 Issue: 2
Author(s): W. Poppe, PH. Simon, W. Tjalma and M. De Ridder
Affiliation:
Keywords: HPV, vaccine, cervical neoplasia, adult women, prevention, review HPV vaccination in adult women
Abstract: Prophyllactic HPV vaccines are efficacious in preventing persistent infections by vaccine-HPV types and related cervical disease. The maximum effect is achieved in women who are not exposed to HPV vaccine types at the time of vaccination (HPV DNA negative women). Todays published data demonstrate equal clinical vaccine efficacy in women between 15 and 26 years and women between 24 and 45 years. The public health effect of vaccinating women older than 25 years is not clear yet, but may be smaller than after vaccination of adolescents. Unresolved issues are duration of protection and long-term preventive effects after treatment of HPV-related disease or natural clearance of HPV infection. Furthermore, it remains difficult to define subgroups of older women who would benefit from the vaccine. It may be that older women exposed to HPV or who are being treated for HPV related disease will benefit most at long term. This needs longer follow-up of vaccinated women and more detailed analysis of data from vaccine trials.
Export Options
About this article
Cite this article as:
Poppe W., Simon PH., Tjalma W. and De Ridder M., HPV Vaccination in Women Above 25 Years: Reasons Why?, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202547
DOI https://dx.doi.org/10.2174/157339410791202547 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Intervening Stemness and Angiogenesis in Cervical Carcinoma: Revisiting the Efficacy of Natural Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design From TGF-β to Cancer Therapy
Current Drug Targets Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study
Recent Patents on Anti-Cancer Drug Discovery Promotion of Cortico-Cerebral Precursors Expansion by Artificial pri-miRNAs Targeted Against the Emx2 Locus
Current Gene Therapy In Silico and In Vitro Analysis of a Multiepitope L1-E7 Fusion Construct for Vaccine Development Against Human Papillomaviruses
Letters in Drug Design & Discovery Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Evaluation of Cytotoxic Mechanisms of Clinacanthus Nutans Extracts in Cancer Cells
The Natural Products Journal Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry